Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

DGAP-News: Biotest AG: Biotest combats climate change through CO2-neutral production: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
DGAP-News: Biotest AG: Biotest combats climate change through CO2-neutral production
DGAP-News: Biotest AG: Biotest combats climate change through CO2-neutral production
HAEMATO vertreibt PCR Point-of-Care Geräte zur wirkungsvollen Eindämmung des Corona-Pandemiegeschehenshttp://www.haemato-ag.de/: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/13910/haematoLogo.png
HAEMATO vertreibt PCR Point-of-Care Geräte zur wirkungsvollen Eindämmung des Corona-Pandemiegeschehens
HAEMATO vertreibt PCR Point-of-Care Geräte zur wirkungsvollen Eindämmung des Corona-Pandemiegeschehens
HAEMATO distributes PCR point-of-care devices for effective containment of corona pandemichttp://www.haemato-ag.de/: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/13910/haematoLogo.png
HAEMATO distributes PCR point-of-care devices for effective containment of corona pandemic
HAEMATO distributes PCR point-of-care devices for effective containment of corona pandemic
Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer


Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for

IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL


IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today

DGAP-News: Biotest AG: Biotest AG opens eighth plasma collection centre in Czech Republic: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
DGAP-News: Biotest AG: Biotest AG opens eighth plasma collection centre in Czech Republic
DGAP-News: Biotest AG: Biotest AG opens eighth plasma collection centre in Czech Republic
DGAP-News: Biotest AG: Biotest AG eröffnet 8. Plasmasammelzentrum in Tschechien: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
DGAP-News: Biotest AG: Biotest AG eröffnet 8. Plasmasammelzentrum in Tschechien
DGAP-News: Biotest AG: Biotest AG eröffnet 8. Plasmasammelzentrum in Tschechien
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital


Regulatory News:



Nanobiotix (Paris:NANO) (NASDAQ:NBTX):



Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website

Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021


Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2021. The financial information

Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones


Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today provided a corporate

Puma Biotechnology Releases Updated Corporate Presentation: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Releases Updated Corporate Presentation


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, provided an update to the corporate presentation that its Chief Executive Officer and President, Alan H. Auerbach, presented at

NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets


Regulatory News:



NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities

DGAP-Adhoc: ​​​​​​​PAION ÜBERTRÄGT CHINESISCHE REMIMAZOLAM-PATENTE UND VERKAUFT DAMIT VERBUNDENE ZUKÜNFTIGE LIZENZGEBÜHREN FÜR EUR 20,5 MIO. AN HUMANWELL HEALTHCARE GROUP: https://upload.wikimedia.org/wikipedia/de/thumb/4/45/Paion-logo.svg/640px-Paion-logo.svg.png
DGAP-Adhoc: ​​​​​​​PAION ÜBERTRÄGT CHINESISCHE REMIMAZOLAM-PATENTE UND VERKAUFT DAMIT VERBUNDENE ZUKÜNFTIGE LIZENZGEBÜHREN FÜR EUR 20,5 MIO. AN HUMANWELL HEALTHCARE GROUP
DGAP-Adhoc: ​​​​​​​PAION ÜBERTRÄGT CHINESISCHE REMIMAZOLAM-PATENTE UND VERKAUFT DAMIT VERBUNDENE ZUKÜNFTIGE LIZENZGEBÜHREN FÜR EUR 20,5 MIO. AN HUMANWELL HEALTHCARE GROUP
DGAP-Adhoc: ​​​​​​​PAION ASSIGNS CHINESE REMIMAZOLAM PATENTS AND SELLS RELATED FUTURE ROYALTIES FOR EUR 20.5 MILLION TO HUMANWELL HEALTHCARE GROUP: https://upload.wikimedia.org/wikipedia/de/thumb/4/45/Paion-logo.svg/640px-Paion-logo.svg.png
DGAP-Adhoc: ​​​​​​​PAION ASSIGNS CHINESE REMIMAZOLAM PATENTS AND SELLS RELATED FUTURE ROYALTIES FOR EUR 20.5 MILLION TO HUMANWELL HEALTHCARE GROUP
DGAP-Adhoc: ​​​​​​​PAION ASSIGNS CHINESE REMIMAZOLAM PATENTS AND SELLS RELATED FUTURE ROYALTIES FOR EUR 20.5 MILLION TO HUMANWELL HEALTHCARE GROUP
DGAP-Adhoc: Biotest AG: Bei Vollzug des Übernahmeangebots wird Grifols, S.A. mehr als 95,5498 % der Stimmrechte halten: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
DGAP-Adhoc: Biotest AG: Bei Vollzug des Übernahmeangebots wird Grifols, S.A. mehr als 95,5498 % der Stimmrechte halten
DGAP-Adhoc: Biotest AG: Bei Vollzug des Übernahmeangebots wird Grifols, S.A. mehr als 95,5498 % der Stimmrechte halten
DGAP-Adhoc: Biotest AG: Grifols, S.A. will hold more than 95,5498 % of the voting rights upon settlement of the takeover offer: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
DGAP-Adhoc: Biotest AG: Grifols, S.A. will hold more than 95,5498 % of the voting rights upon settlement of the takeover offer
DGAP-Adhoc: Biotest AG: Grifols, S.A. will hold more than 95,5498 % of the voting rights upon settlement of the takeover offer
argenx Highlights Strategic Priorities for 2022
argenx Highlights Strategic Priorities for 2022


Regulatory News:



argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its strategic

Transgene Announces Financial Calendar for 2022: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene Announces Financial Calendar for 2022


Regulatory News:



TRANSGENE (Paris: TNG) today announced its financial reporting dates for 2022:



March 16, 2022: 2021 Fiscal Year Results



May 10, 2022: First Quarter 2022 Financial Results

Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that Sanofi will be transitioning its rights and obligations related to SAR445136, a zinc finger nuclease

NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer


Regulatory News:



NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX – the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for

IMV Inc. to Present at Two Upcoming Investor Events: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Inc. to Present at Two Upcoming Investor Events


IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematological cancers today

Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will provide a corporate presentation at the H.C. Wainwright BIOCONNECT Virtual Conference on

Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022


Regulatory News:



NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities

Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the management team will participate in two upcoming virtual investor conferences.




  • H.C. Wainwright

Puma Biotechnology to Present at the H.C. Wainwright BioConnect Conference: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology to Present at the H.C. Wainwright BioConnect Conference


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of